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DEFINITION OF TECHNOLOGY 
READINESS LEVELS (TRL) 
AND APPLICATION 
TO BIOMEDICAL FIELD
Adriano Savoini & Alessandro Tronchin
T&B e associati S.r.l., c/o AREA Science Park, Padriciano 99, 34149 Trieste
Description of the various Levels, corresponding phase (if any) of the Product Design 
process according to ISO9000 rules, actors involved and scenarios.
TRL 1 BASIC PRINCIPLES OBSERVED AND REPORTED: Lowest level of technology readiness. 
Scientific research begins to be translated into applied research and development.
Biomedical field: Active monitoring of scientific knowledge base. Scientific findings are reviewed and 
assessed as a possible foundation for characterizing new technologies
ISO 9000 Project phase: preliminary phase and brain-storming
Actors: Scientist, Researcher, Technician, R&D people
Scenario: Observation might be done by operators acting in a different field / scientific area and 
reported in literature, congresses, blogs, etc.
TRL 2 TECHNOLOGY CONCEPT AND/OR APPLICATION FORMULATED: Invention begins. Once 
basic principles are observed, practical applications can be invented. Applications are speculative and 
there may be no proof or detailed analysis to support the assumptions.
Biomedical field: Scientific “paper studies” can generate research ideas, hypotheses, and experimental 
designs for addressing the related scientific issues. Focus on practical applications based on basic 
principles observed. Use of computer simulation or other virtual platforms to test hypotheses
ISO 9000 Project phase: preliminary phase and brain-storming
Actors: Laboratory team leader, Scientist, Researcher, Marketing & Finance people, IP specialist, 
Regulatory Affairs, Opinion leaders
Scenario: It’s the inventive step! Tech concepts are transferred to product/service/application 
hypothesis. Budget / Market forecasts / IP strategies come into play. Focus groups with opinion leaders 
are used to test the product concept
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TRL 3 ANALYTICAL AND EXPERIMENTAL CRITICAL FUNCTION AND/OR CHARACTERISTIC 
PROOF-OF-CONCEPT: Active research and development is initiated. This includes analytical studies 
and laboratory studies to physically validate analytical predictions of separate elements of the 
technology.
Biomedical field: Begin research, data collection, and analysis in order to test hypothesis. Explore 
alternative concepts, identify and evaluate critical technologies and components, and begin 
characterization of candidate. Preliminary efficacy demonstrated in vitro
ISO 9000 Project phase: Feasibility study
Actors: Research and Development (mainly), Manufacturing
Scenario: Key points (usually the most uncertain ones) are carefully examined to demonstrate the 
“Project” is feasible, both on the tech and financial side. Scientists provide support and guidance to 
solve specific problems. This step will provide a GO / NO GO result ! 
TRL 4 COMPONENT/SUBSYSTEM VALIDATION IN LABORATORIAL ENVIRONMENT:  Basic 
technological components are integrated to establish that they will work together. This is relatively 
“low fidelity” compared to the eventual system.
Biomedical field: Integration of critical technologies for candidate development. Initiation of animal 
model development. In vitro toxicity and efficacy demonstration in accordance with the product’s 
intended use. Initiation of experiments to identify markers, correlates of protection, assays, and 
endpoints for further non-clinical and clinical studies.
• Animal Models: Initiate development of appropriate and relevant animal model(s) for the desired 
indications.
• Assays: Initiate development of appropriate and relevant assays and associated reagents for the 
desired indications.
• Manufacturing: Manufacture laboratory-scale, quantities of bulk product and proposed formulated 
product.
ISO 9000 Project phase: Prototype optimization
Actors: Research and Development (mainly)
Scenario: Prototype is developed to its full performance potential, but still in a lab environment
TRL 5 SYSTEM/SUBSYSTEM/COMPONENT VALIDATION IN RELEVANT ENVIRONMENT: Fidelity 
of breadboard technology increases significantly. The basic technological components are integrated 
with reasonably realistic supporting elements so it can be tested in a simulated environment.
Biomedical field:  Continue  in vitro studies, and animal model and assay development. Establish draft 
Target Product Profiles. Develop a scalable and reproducible manufacturing process.
• Animal Models: Continue development of animal models for efficacy and dose-ranging studies.
• Assays: Initiate development of in-process assays and analytical methods for product characterization 
and release, including assessments of potency, purity, identity, strength, sterility, and quality as 
appropriate.
• Manufacturing: Initiate process development for small-scale manufacturing
ISO 9000 Project phase: Prototype optimization
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Actors: Research and Development (mainly), external consultants, key customers, opinion leaders
Scenario: Once lab prototypes are available and internally tested, first tests out of R&D start, so first 
feedback from users can be acquired.
TRL 6 SYSTEM/SUBSYSTEM MODEL OR PROTOTYPING DEMONSTRATION IN A RELEVANT END-
TO-END ENVIRONMENT: Representative model or prototype system, which is well beyond that of 
TRL 5, is tested in a relevant environment. Represents a major step up in a technology’s demonstrated 
readiness.
Biomedical field: Prepare and submit Investigational New Drug package to EFSA and conduct Phase 
1 clinical trial to determine the safety and pharmacokinetics of the clinical test article.
• Animal Models: Continue animal model development via toxicology, pharmacology, and 
immunogenicity studies.
• Assays: Qualify assays for manufacturing quality control and immunogenicity, if applicable.
• Manufacturing: Manufacture, release and conduct stability test and formulated product in support of 
the clinical trial.
ISO 9000 Project phase: Industrialization
Actors: Research and Development, external consultants, key customers, opinion leaders, 
industrialisation (mainly), manufacturing
Scenario: Scale-up process begins. Precise feedback from users is required so to draft final product 
technical specifications. Part list and precise costing sheet is finalised
TRL 7 SYSTEM PROTOTYPING DEMONSTRATION IN AN OPERATIONAL ENVIRONMENT: 
Prototype near, or at, planned operational system. Represents a major step up from TRL 6, requiring 
demonstration of an actual system prototype in an operational environment.
Biomedical field: Scale-up and initiate validation of  manufacturing process. Conduct animal efficacy 
studies as appropriate. Conduct Phase 2 clinical trials.
• Animal Models: Refine animal model development in preparation for pivotal animal efficacy studies.
• Assays: Validate assays for manufacturing quality control and immunogenicity if applicable.
• Manufacturing: Scale-up and validate manufacturing process at a scale compatible with specific 
requirements. Begin stability studies of the product in a formulation, dosage form, and container 
consistent with Target Product Profile. Initiate manufacturing process validation and consistency lot 
production.
ISO 9000 Project phase: Industrialization
Actors: Research and Development, industrialisation (mainly), manufacturing, QC, purchasing dept, 
finance
Scenario: Internal validation, QC process and release procedures are finalised. Financial management 
of future product is developed
TRL 8 ACTUAL SYSTEM COMPLETED AND “MISSION QUALIFIED” THROUGH TEST AND 
DEMONSTRATION IN AN OPERATIONAL ENVIRONMENT: Technology has been proven to work 
in its final form and under expected conditions. In almost all cases, this TRL represents the end of true 
system development
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Biomedical field: finalize manufacturing process. Complete pivotal animal efficacy studies or clinical 
trials (e.g., Phase 3), and/or expanded clinical safety trials as appropriate. Prepare and submit NDA.
• Manufacturing: Complete validation and manufacturing of consistency lots at a scale compatible with 
specific requirements. Complete stability studies in support of label expiry dating.
ISO 9000 Project phase: Validation of  industrial prototype
Actors: Research and Development, Industrialization, Manufacturing, QC, Marketing (mainly), Sales, 
external testing sites, Regulatory Affairs
Scenario: External validation in reference centres according to a pre-defined protocol. Final draft of 
regulatory documentation for CE Mark or other regulatory approvals.
TRL 9 ACTUAL SYSTEM “MISSION PROVEN” THROUGH SUCCESSFUL MISSION OPERATIONS: 
Actual application of the technology in its final form and under mission conditions, such as those 
encountered in operational test and evaluation.
Biomedical field: Commence post-licensure/post-approval and Phase 4 studies (post-marketing 
commitments), such as safety surveillance, studies to support use in special populations, and clinical 
trials to confirm safety and efficacy as feasible and appropriate.
ISO 9000 Project phase:  Product launch on the market and monitoring in the market
Actors: Research and Development, manufacturing, logistic, Marketing (mainly), Sales, QC, media
Scenario: End of product development process and start of distribution activities through sale force 
or distributors. Acquisition of further inputs from the market (sales force, operators, customers) useful 
for future product / process improvements is started.
NOTE:
• This document has been drafted on the basis of the first TRL scale developed in 1974 by NASA 
researcher Stan Sadin.
• Comments on biomedical field are based on the Guidelines issued by the School of Pharmacy of the 
University of Southern California.
• This document has been drafted by Adriano Savoini & Alessandro Tronchin (T&B Associati s.r.l) and first 
presented to Trans2Care meeting at Nova Gorica University (Vipava location) on December 20, 2013; 
updated version was discussed at the CBC Italy-Slovenia BioMed Conference on February 27, 2014. 
A further updated version was drafted on May 23, 2014 including description of specific scenarios and 
actors involved at the various stages.
